TLN-499 with venetoclax for advanced solid tumors that returned or stopped responding
Tests TLN-499 with venetoclax in adults with solid tumors that came back.
Plain-language title generated from the registry record
Registry title: TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
Key facts
- Where
- Camperdown, Malvern, and Nedlands, AustraliaSee the 3 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose small cell lung cancer, neuroendocrine cancer, malignant pleural mesothelioma or synovial sarcoma came back or did not respond to treatment. They must have disease that can be measured.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory (came back or did not respond to treatment) small cell lung cancer, neuroendocrine cancer, malignant pleural mesothelioma or synovial sarcoma, confirmed by tissue examination. The disease must be measurable (RECIST v1.1 or mRECIST). ECOG performance status 0-1.
Main reasons for not taking part
- Active brain metastases
- Major surgery or severe trauma within 4 weeks before the first dose
- Significant uncontrolled medical conditions that prevent taking part
- Use of prohibited medicines taken at the same time
- Life expectancy under 12 weeks
Read by machine on 9 November 2026.
Where in Australia
- COBL Clinical Trials - Chris O'Brien LifehouseCamperdown, AustraliaNot yet recruiting
- Cabrini Hospital - MalvernMalvern, AustraliaNot yet recruiting
- Linear Clinical ResearchNedlands, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Treeline Biosciences, Inc.
- Trial code
- NCT07713732
- Record updated
- 1 October 2026
- Original description
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.Read full original descriptionShow less
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
Inclusion: Adults ≥18 years of age; Histologically confirmed relapsed/refractory SCLC, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma; Measurable disease per RECIST v1.1 or mRECIST; ECOG performance status 0-1; Adequate hematologic, hepatic, renal, and coagulation function; Life expectancy ≥12 weeks; Signed informed consent.
Exclusion: Major surgery or severe trauma within 4 weeks before first dose; Use of prohibited concomitant medications; Previous conditions that would interfere with study assessments or safety; Significant uncontrolled medical conditions preventing study participation; Active brain metastases.